FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA page indicates Takeda submitted a supplemental NDA for AGRYLIN (anagrelide hydrochloride), signaling a labeling change under review.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• AGRYLIN (ANAGRELIDE HYDROCHLORIDE)

Snippet

SUPPL AP for AGRYLIN (ANAGRELIDE HYDROCHLORIDE)